Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.68 |
| ▸ | GCGR | P47871 | 7/20 | 0.56 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.56 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.56 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.56 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.56 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.56 |
| ▸ | FRK | P42685 | 1/20 | 0.56 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.56 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.56 |
| ▸ | GSK3B | P49841 | 1/20 | 0.56 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.56 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.56 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.56 |
| ▸ | BRAF | P15056 | 1/20 | 0.54 |
| ▸ | RAF1 | P04049 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11180564 | 0.88 | ALDH1A1 (0.50) | MAPK14GCGRMAPK13MAPK12MAPK11 | |
| SCHEMBL6937157 | 0.84 | MAPK14 (0.64) | MAPK14GCGRMAPK13MAPK12MAPK11 | |
| SCHEMBL828544 | 0.81 | MAPK14 (0.55) | MAPK14GCGRMAPK13MAPK12MAPK11 | |
| SCHEMBL4462710 | 0.81 | MAPK14 (0.50) | MAPK14GCGRMAPK13MAPK12MAPK11 | |
| SCHEMBL4461255 | 0.81 | GCGR (0.58) | MAPK14GCGRMAPK13MAPK12MAPK11 | |
| SCHEMBL4470689 | 0.80 | NOTUM (0.56) | MAPK14GCGRMAPK13MAPK12MAPK11 | |
| SCHEMBL4472359 | 0.79 | MAPK14 (0.55) | MAPK14GCGRMAPK13MAPK12MAPK11 | |
| SCHEMBL4096702 | 0.79 | MAPK14 (0.44) | MAPK14GCGRMAPK13MAPK12MAPK11 | |
| SCHEMBL14033245 | 0.77 | MAPK14 (0.54) | MAPK14GCGRMAPK13MAPK12MAPK11 | |
| SCHEMBL5091913 | 0.77 | MAPK14 (0.54) | MAPK14GCGRMAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170313661-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2017-11-02 | — | — | US | disclosed |
| US-9617221-B2 | Kinase modulators for the treatment of cancer | SYNOVO GMBH (DE) | 2017-04-11 | — | — | US | disclosed |
| US-8461120-B2 | Macrocyclic compounds pounds and methods of use thereof | SYNOVO GMBH (DE) | 2013-06-11 | — | — | US | disclosed |
| US-20130045938-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2013-02-21 | — | — | US | disclosed |
| US-20110028417-A1 | Macrocyclic Compounds and Methods of Use Thereof | SYNOVO GMBH (DE) | 2011-02-03 | — | — | US | disclosed |
| US-7767797-B1 | Macrocyclic compounds and methods of use thereof | SYNOVO GMBH (DE) | 2010-08-03 | — | — | US | disclosed |
| US-7582660-B2 | 2-thio-substituted imidazole derivatives and their use in pharmaceutics | C-A-I-R BIOSCIENCES GMBH (DE) | 2009-09-01 | — | — | US | disclosed |
| US-7582660-B2 | 2-thio-substituted imidazole derivatives and their use in pharmaceutics | C-A-I-R BIOSCIENCES GMBH (DE) | 2009-09-01 | — | — | US | disclosed |
| US-7582660-B2 | 2-thio-substituted imidazole derivatives and their use in pharmaceutics | C-A-I-R BIOSCIENCES GMBH (DE) | 2009-09-01 | — | — | US | disclosed |
| US-20060235054-A1 | 2-Thio-substituted imidazole derivatives and their use in pharmaceutics | MERCKLE-GMBH (DE) | 2006-10-19 | — | — | US | disclosed |
| EP-1539741-A1 | 2-THIO-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE IN PHARMACEUTICS | MERCKLE GMBH (DE) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004018458-A1 | 2-THIO-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE IN PHARMACEUTICS | MERCKLE-GMBH (DE) | 2004-03-04 | — | — | WO | disclosed |
| US-6432988-B1 | RHEUMATIC DISEASES, (OSTEO)ARTHRITIS, CACHEXIA, INFLAMMATORY BOWEL DISEASE, TOXIC SHOCK SYNDROME, SEPSIS, CROHN*S DISEASE, PSORIASIS AND GOUT TREATMENT | MERCKLE GMBH (DE) | 2002-08-13 | — | — | US | disclosed |
| US-4847270-A | ANTIINFLAMMATORY AGENTS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-07-11 | — | — | US | disclosed |
| US-4728656-A | ANTIARTHRITIC, ANTIINFLAMMATORY | SMITHKLINE BECKMAN CORPORATION (US) | 1988-03-01 | — | — | US | disclosed |
| WO-1988001168-A1 | INHIBITION OF INTERLEUKIN-1 BY MONOCYTES AND/OR MACROPHAGES | SMITHKLINE BECKMAN CORPORATION (US) | 1988-02-25 | — | — | WO | disclosed |
| US-4175127-A | ANTIARTHRITIC AGENTS | SMITHKLINE CORPORATION (US) | 1979-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028417-A1 | Macrocyclic Compounds and Methods of Use Thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PCSK9, CYP11B2 | MAPK14 3779/4885GCGR 1751/4885MAPK13 3611/4885 |
| US-20170313661-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | MAP3K10, MAP3K12, MAP3K20 | MAPK14 53/4885GCGR 3738/4885MAPK13 71/4885 |
| US-20130045938-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | MAP3K10, MAP3K12, MAP3K20 | MAPK14 53/4885GCGR 3738/4885MAPK13 71/4885 |
| US-20060235054-A1 | 2-Thio-substituted imidazole derivatives and their use in pharmaceutics | IL2, TPMT, IFNG | MAPK14 3841/4885GCGR 2154/4885MAPK13 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.